Physician profile
Ester B Cerdan
NPI 1457691172
$9,528.59
in general payments reported to CMS, 2019-2025
32 companies · $2,394 in 2025
The $2,394 reported for 2025 was more than what 95% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $590 · 2022: $1,383 · 2023: $2,369 · 2024: $2,792 · 2025: $2,394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,790 · Travel and Lodging: $1,765.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,789.96 |
| Travel and Lodging | $1,765.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $1,392.62 | 2023-2025 | Barostim Neo System |
| Boston Scientific Corporation | $1,289.73 | 2024 | Emblem Mri S-Icd |
| Abbvie INC. | $949.05 | 2021-2025 | |
| Impulse Dynamics (USA) INC. | $781.00 | 2023-2025 | Optimizer, Optimizer |
| La Jolla Pharmaceutical Company | $663.12 | 2021-2025 | Zevtera, Giapreza, Xacduro |
| Astrazeneca Pharmaceuticals LP | $468.03 | 2021-2024 | Andexxa |
| Inspire Medical Systems, INC. | $422.61 | 2023-2024 | Inspire |
| Amgen INC. | $362.59 | 2025 | |
| Gilead Sciences, INC. | $346.82 | 2023-2025 | Livdelzi, Epclusa |
| Abbott Laboratories | $300.98 | 2022-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Genzyme Corporation | $231.90 | 2021-2023 | |
| Mallinckrodt Hospital Products INC. | $229.90 | 2024-2025 | Terlivaz |
| Merck Sharp & Dohme LLC | $224.40 | 2022-2025 | Zerbaxa |
| Shionogi INC | $219.84 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $191.63 | 2022-2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $125.01 | 2024 | Uptravi, Opsumit |
| Sobi, INC | $125.00 | 2024 | |
| Alcresta Therapeutics, INC. | $124.08 | 2025 | Relizorb |
| Horizon Therapeutics Plc | $123.32 | 2023 | Uplizna |
| Xeris Pharmaceuticals, INC. | $122.33 | 2024 | Gvoke Hypopen |
| Ultragenyx Pharmaceutical INC. | $105.86 | 2022 | |
| Idorsia Pharmaceuticals US INC | $96.19 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $96.19 | 2025 | |
| Eisai INC. | $84.38 | 2025 | |
| Pfizer INC. | $81.49 | 2022 | |
| Btg International INC. | $77.26 | 2024 | |
| Biogen, INC. | $68.61 | 2023 | |
| Coloplast Corp | $53.81 | 2023 | Titan, Altis |
| Janssen Pharmaceuticals, INC | $49.99 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.62 | 2022 | |
| Lantheus Medical Imaging, INC. | $39.42 | 2023 | Definity |
| Fresenius USA Marketing, INC. | $35.81 | 2024 | Nxstage System One |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ester Cerdan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.